CoChat
Sign Up
Cited by 61Growth Hormone and Insulin-like Growth FactorsGenetic and Clinical Aspects of Sex Determination and Chromosomal AbnormalitiesImmunodeficiency and Autoimmune Disorders

Growth hormone treatment before the age of 4 years prevents short stature in young girls with Turner syndrome

Linglart, A, Cabrol, S, Berlier, P, Stuckens, C, Wagner, K, de Kerdanet, M, Limoni, C, Carel, J-C +2 more·2011·European Journal of Endocrinology
DOI 10.1530/eje-10-1048
Open this paper in CoChat — free account

Abstract

OBJECTIVE: Adult height deficit seen in Turner syndrome (TS) originates, in part, from growth retardation in utero and throughout the first 3 years of life. Earlier diagnosis enables earlier therapeutic intervention, such as with recombinant human GH (r-hGH), which may help to prevent growth retardation. In this open-label, multicentre phase III study, we investigated efficacy and safety in r-hGH treatment in young girls with TS. SUBJECTS AND METHODS: Girls (n=61) aged <4 years with TS receiving 0.035-0.05 mg/kg per day r-hGH for 4 years were compared with an historical control group (n=51) comprising untreated, age- and height-matched girls with TS. The main outcome measure was change in height SDS (H-SDS). Other measures included changes in height velocity SDS, IGF1 levels and glucose metabolism. RESULTS: After 4 years, a gain in mean H-SDS of 1.0 SDS (from -2.33±0.73 to -1.35±0.86 SDS) was observed with r-hGH treatment, in contrast to the decrease in mean H-SDS of 0.3 SDS in the control group (from -2.09±0.81 to -2.44±0.73 SDS; P<0.0001). r-hGH treatment was the main predictor of H-SDS gain and accounted for 52% of variability (multivariate analysis). r-hGH was well tolerated. As expected, IGF1 levels rose with treatment. A case of transient glucose intolerance resolved after dietary adaptation. CONCLUSION: Early treatment with r-hGH helps to prevent natural evolution towards short stature in most girls with TS. IGF1 levels and glucose metabolism should be monitored routinely during r-hGH therapy.

Integrity signals

Registry

Crossref · 10.1530/eje-10-1048

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Younger age at treatment initiation, including at least 4 years of treatment prior to puberty, is associated with greater GH treatment effect.

    “Younger age at treatment initiation,158,162,163 including at least 4 years of treatment prior to puberty,175,179,180 is associated with greater GH treatment effect.”

    From Clinical practice guidelines for the care of girls and women with Turner syndrome. (2024) · cites this paper as [179]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Linglart, A., Cabrol, S., Berlier, P., Stuckens, C., Wagner, K., de Kerdanet, M., Limoni, C., Carel, J.-C., Chaussain, J.-L., & _, _.
Affiliations
  • Inserm (FR)
  • Hôpital Armand-Trousseau (FR)
  • Hôpital Femme Mère Enfant (FR)
  • Hôpital Jeanne de Flandre (FR)
  • Hôpital l'Archet (FR)
  • Hôpital Robert-Debré (FR)
Corresponding author
Linglart, A
ORCID
Venue
European Journal of Endocrinology
Publisher
Oxford University Press (OUP)
Published
2011-06
Volume
164
Issue
6
Pages
891-897
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
DOI
10.1530/eje-10-1048
OpenAlex
W2114976776
Cited by
61
References
31
Citations by year
2026: 1 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 2 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 5 · 2016: 4 · 2015: 4 · 2014: 3 · 2013: 6 · 2012: 8
FWCI
4.45
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
  • Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Keywords
Turner syndrome, recombinant human growth hormone, height SDS, height velocity, insulin-like growth factor I, impaired glucose tolerance, growth retardation
MeSH terms
Age Determination by Skeleton, Blood Cell Count, Blood Glucose, Body Height, Child, Preschool, Female, Growth, Glycated Hemoglobin, Humans, Infant, Insulin-Like Growth Factor I, Karyotyping, Liver Function Tests, Longitudinal Studies, Growth Hormone, Turner Syndrome, Treatment Outcome, Carbohydrate Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review